Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che‐Hung Shen(Kaohsiung Medical University), Bin Zheng(Harvard University), Devarati Mitra(Brigham and Women's Hospital), Keith T. Flaherty(Cancer Research Center), Sun Hye Kim(Harvard University), Ping Yuan(Anhui Medical University), Dennie T. Frederick(Broad Institute), Sebastian Trousil(Harvard University), Li Cai(Harvard University), David E. Fisher(Massachusetts General Hospital), Man Li(Second Affiliated Hospital of Jilin University), Jung‐Hyun Lee(University of Seoul), Ryan J. Sullivan(Dana-Farber Cancer Institute), Lei Gu(Max Planck Institute for Heart and Lung Research), Adriano Piris(Brigham and Women's Hospital)
Cited by 90
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k